Compass Pathways Plc (CMPS)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ
Market Cap: $1.28B
Last updated: Nov 17, 2026 at 11:04 AM ET
Compass Pathways Plc (CMPS) Earnings: Report Dates and Results
Compass Pathways Plc (CMPS) is expected to report earnings on Mar 22, 2027. In the quarter ended Sep 30, 2026, Compass Pathways Plc reported EPS of -$0.31, above the -$0.39 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CMPS has an expected report date of Mar 22, 2027.
CMPS Earnings Call
The latest CMPS earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 26 quarters below that had an estimate, CMPS beat 16, missed 9 and matched 1. The widest gap in the table came in the quarter ended Dec 31, 2020, when EPS landed 62.59% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.31 | -$0.39 | -$0.41 - -$0.25 | +20.51% | Beat | N/A | 4 | 0 up, 1 down | Nov 3, 2026 |
| Jun 30, 2026 | -$0.36 | -$0.46 | N/A | +21.74% | Beat | N/A | 4 | 0 up, 0 down | Aug 5, 2026 |
| Mar 31, 2026 | -$0.30 | -$0.31 | -$0.35 - -$0.28 | +3.23% | Beat | N/A | 2 | 1 up, 1 down | May 13, 2026 |
| Dec 31, 2025 | -$0.61 | -$0.40 | -$0.42 - -$0.36 | -52.66% | Miss | N/A | 2 | 2 up, 0 down | Mar 24, 2026 |
| Sep 30, 2025 | -$0.38 | -$0.40 | -$0.41 - -$0.40 | +5.00% | Beat | N/A | 2 | 2 up, 0 down | Nov 4, 2025 |
| Jun 30, 2025 | -$0.41 | -$0.37 | -$0.37 - -$0.37 | -10.81% | Miss | N/A | 2 | 2 up, 0 down | Jul 31, 2025 |
| Mar 31, 2025 | -$0.42 | -$0.49 | -$0.67 - -$0.41 | +14.29% | Beat | N/A | 5 | 1 up, 0 down | May 8, 2025 |
| Dec 31, 2024 | -$0.63 | -$0.63 | -$0.75 - -$0.56 | 0.00% | In line | N/A | 7 | 1 up, 3 down | Feb 27, 2025 |
| Sep 30, 2024 | -$0.56 | -$0.59 | -$0.68 - -$0.48 | +5.08% | Beat | N/A | 9 | 0 up, 0 down | Oct 31, 2024 |
| Jun 30, 2024 | -$0.56 | -$0.55 | -$0.65 - -$0.44 | -1.82% | Miss | N/A | 7 | 0 up, 0 down | Aug 1, 2024 |
| Mar 31, 2024 | -$0.55 | -$0.49 | -$0.68 - -$0.28 | -12.24% | Miss | N/A | 5 | 0 up, 0 down | May 8, 2024 |
| Dec 31, 2023 | -$0.53 | -$0.34 | -$0.62 - -$0.24 | -55.88% | Miss | N/A | 5 | 0 up, 0 down | Feb 29, 2024 |
| Sep 30, 2023 | -$0.67 | -$0.42 | -$0.63 - -$0.19 | -59.52% | Miss | N/A | 7 | 1 up, 0 down | Nov 2, 2023 |
| Jun 30, 2023 | -$0.62 | -$0.70 | -$0.81 - -$0.62 | +11.43% | Beat | N/A | 8 | 0 up, 0 down | Aug 3, 2023 |
| Mar 31, 2023 | -$0.57 | -$0.65 | -$0.81 - -$0.50 | +12.31% | Beat | N/A | 8 | 0 up, 0 down | May 11, 2023 |
| Dec 31, 2022 | -$0.73 | -$0.59 | -$0.69 - -$0.46 | -23.73% | Miss | N/A | 8 | 0 up, 0 down | Feb 28, 2023 |
| Sep 30, 2022 | -$0.43 | -$0.64 | -$0.73 - -$0.55 | +32.81% | Beat | N/A | 9 | 1 up, 0 down | Nov 3, 2022 |
| Jun 30, 2022 | -$0.50 | -$0.60 | -$0.66 - -$0.49 | +16.67% | Beat | N/A | 8 | 0 up, 0 down | Aug 4, 2022 |
| Mar 31, 2022 | -$0.50 | -$0.67 | -$0.73 - -$0.61 | +25.37% | Beat | N/A | 7 | 0 up, 0 down | May 10, 2022 |
| Dec 31, 2021 | -$0.61 | -$0.50 | -$0.60 - -$0.41 | -22.00% | Miss | N/A | 9 | 0 up, 0 down | Feb 24, 2022 |
| Sep 30, 2021 | -$0.38 | -$0.47 | -$0.57 - -$0.42 | +19.15% | Beat | N/A | 9 | N/A | Nov 9, 2021 |
| Jun 30, 2021 | -$0.44 | -$0.37 | -$0.45 - -$0.30 | -18.92% | Miss | N/A | 8 | N/A | Aug 11, 2021 |
| Mar 31, 2021 | -$0.35 | -$0.47 | -$0.72 - -$0.33 | +25.53% | Beat | N/A | 4 | N/A | May 13, 2021 |
| Dec 31, 2020 | -$0.52 | -$1.39 | -$2.42 - -$0.36 | +62.59% | Beat | N/A | 3 | N/A | Mar 9, 2021 |
| Sep 30, 2020 | -$0.46 | -$0.68 | -$0.77 - -$0.33 | +32.35% | Beat | N/A | 3 | N/A | Nov 12, 2020 |
| Jun 30, 2020 | -$0.19 | -$0.35 | N/A | +45.71% | Beat | N/A | N/A | N/A | Sep 21, 2020 |
| Dec 31, 2019 | -$0.35 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2019 |
| Sep 30, 2019 | -$0.26 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2019 |
| Jun 30, 2019 | -$0.45 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 30, 2019 |
| Mar 31, 2019 | -$0.48 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2019 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.82, after -$2.30 the year before. It was -$2.35 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.82 | N/A |
| Dec 31, 2024 | -$2.30 | N/A |
| Dec 31, 2023 | -$2.39 | N/A |
| Dec 31, 2022 | -$2.16 | N/A |
| Dec 31, 2021 | -$1.78 | N/A |
| Dec 31, 2020 | -$1.17 | N/A |
| Dec 31, 2019 | -$0.90 | N/A |
| Dec 31, 2018 | -$2.35 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,200 words across 19 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,210 | 19 | |
| 2026Q2 | Jun 30, 2026 | 5,875 | 17 | |
| 2026Q1 | Mar 31, 2026 | 7,911 | 17 | |
| 2025Q3 | Sep 30, 2025 | 4,392 | 13 | |
| 2025Q2 | Jun 30, 2025 | 4,094 | 14 | |
| 2025Q1 | Mar 31, 2025 | 2,487 | 9 | |
| 2024Q4 | Dec 31, 2024 | 5,805 | 17 | |
| 2024Q3 | Sep 30, 2024 | 6,200 | 17 |
2026Q3 Earnings Call
Opening remarks
Stephen Schultz Senior Vice President of Investor Relations Welcome, all of you, and thank you for joining us today for this conference call. Again, my name is Steve Schultz, Senior Vice President of Investor Relations at Compass Pathways. Today, I am joined by Kabir Nath, our Chief Executive Officer, and Lori Englebert, our Chief Commercial Officer. Dr. Steve Levine, our Chief Patient Officer, and Teri Loxam, our Chief Financial Officer, will also be available for the Q&A. The call is being recorded and will be available on the Compass Pathways Investor Relations website shortly after the conclusion of the call, and will be available for a period of 30 days. Before we begin, let me remind everyone that during the call today, we will be making statements about our future plans and prospects that constitute forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement, including those risks and uncertainties described under the heading "Risk Factors" in our most recent filings with the U.S. Securities and Exchange Commission. These forward-looking statements represent our views only as of today, and we specifically disclaim any obligation to update or revise any forward-looking statement, even if our estimates or assumptions change. I will now hand the call to Kabir Nath.
Kabir Nath CEO Thank you, Steve, and thank you all for joining us today. Compass continues to make excellent progress toward the potential FDA approval of our psychedelic treatment, which will fundamentally change how mental health is managed. Today, for the estimated 4 million individuals in the U.S. who are impacted by treatment-resistant depression, there is only one approved and marketed drug with that indication, and fewer than 3% of those patients are actually being treated with it. COMP360's profile is unique and compellingly differentiated in delivering both a rapid onset, with effects seen within 24 hours, and durability potentially out to 12 months with just a few treatments. The data also show a safety profile that is generally well tolerated. We're confident that COMP360's efficacy in this difficult-to-treat patient population, along with a much less frequent administration schedule, will be highly attractive to patients and prescribers, a confidence that's been well supported by the recent market research that we've been conducting. We will complete our rolling NDA submission in the next two weeks. We have ensured that the filing is the highest quality, with two highly statistically significant phase III studies, together with a positive phase II-B study that together enrolled over 1,000 patients. This will enable the agency to review it with its usual scientific rigor.
Frequently Asked Questions About CMPS
When is Compass Pathways Plc's next earnings date?
Compass Pathways Plc's next earnings report is expected for Mar 22, 2027.
Did CMPS beat earnings estimates last quarter?
Yes. Compass Pathways Plc reported EPS of -$0.31 for the quarter ended Sep 30, 2026, above the -$0.39 estimate, a 20.51% surprise.
What EPS do analysts expect from CMPS next quarter?
The consensus EPS estimate for Compass Pathways Plc for the quarter ending Dec 31, 2026 is -$0.47 from 17 analysts, with estimates from -$0.59 to -$0.34.
How often does CMPS beat earnings estimates?
Compass Pathways Plc beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +0.16%.
CMPS pages: Overview, Earnings, Forecast, Financials, Competitors